Trial Profile
An International, Multi-Center, Open Label, Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix versus Goserelin Depot (Zoladex) in Men with Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Ozarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 03 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Aug 2012 Planned number of patients changed from 214 to 300.